Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer - 1 Jan 2016

Ahire Vidhula, Das D, Mishra Kaushala Prasad, Kulkarni G R, Ackland L

Abstract excerpt

Y220C, a substitution mutation in p53, causes major structural changes in the protein and is known to form a new protein cavity. This cavity is reckoned to accommodate small drug candidates that may play a key role in cancer treatment. Present study was aimed at determining a drug candidate that could inhibit the mutant p53 based on structural drug rationale. Docking of mutated p53 was performed to determine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthraquinones
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 27992315
DOI: 10.1615/JEnvironPatholToxicolOncol.2016012256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.PMID 27992315Read ↗

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.Semantic proximity Read ↗

Flavonoids as potential reactivators of structural mutation p53Y220C by computational and cell-based studies.Semantic proximity Read ↗

Uncovering the Natural Inhibitors From Medicinal Plants to Alleviate Human Cancers Targeting the p53 Protein: An In Silico ApproachSemantic proximity Read ↗

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220CSemantic proximity Read ↗

Small molecule induced reactivation of mutant p53 in cancer cells.Semantic proximity Read ↗

The role of p53 in cancer drug resistance and targeted chemotherapy.Semantic proximity Read ↗

Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.Semantic proximity Read ↗

Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties.Semantic proximity Read ↗

Novel Bcl‐2 Inhibitors: Discovery and Mechanism Study of Small Organic Apoptosis‐Inducing AgentsSemantic proximity Read ↗

Protein interactions, molecular docking, antimicrobial and antifungal studies of terpyridine ligandsSemantic proximity Read ↗

Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD.Semantic proximity Read ↗

Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.